Newly created role of Chief Patient Officer reinforces Compass’ vision of working to achieve broad and equitable access to COMP360, if approved LONDON & NEW YORK / Jan 21, 2025 / Business Wire / Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Steve Levine, M.D., as Chief Patient Officer,... Read More

LONDON & NEW YORK / Jan 10, 2025 / Business Wire / Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (“ADSs”) and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS... Read More

LONDON / Dec 18, 2024 / Business Wire / Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today its common stock will be added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 23, 2024. The NASDAQ Biotechnology Index is designed to track the performance of a set of... Read More

LONDON & NEW YORK / Nov 25, 2024 / Business Wire / Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of the executive management team will participate in the following investor conferences in addition to hosting investor meetings: 7 th Annual Evercore ISI HealthCONx Conference: Fireside chat at... Read More

Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025 COMP006 data will now be announced after 26-week time point, expected in the second half of 2026 Strategic reorganization to focus all efforts on COMP360 program resulting in reduction of workforce of approximately 30% Cash position of $207 million Conference call October 31 at 8:00 am ET (12:00 pm... Read More

LONDON / Oct 24, 2024 / Business Wire / Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2024 ending September 30, 2024, and provide an update on recent business developments, on October 31, 2024. The management team will host a conference call at... Read More

LONDON & NEW YORK / Sep 23, 2024 / Business Wire / Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, announced today that executives from the management team will be participating in a fireside chat at the Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit on September 26, 2024 at 1:20pm ET. A live audio... Read More

Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million Conference call August 1 at 8:00 am ET (1:00 pm UK) LONDON and NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a... Read More

New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatment Latest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access... Read More

COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025 Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD) Michael Gold to join Compass as Head of R&D Compass enters into additional commercial collaborations, including with Reliant Medical Group, part of Optum... Read More

Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5 point reduction at week 12), with change from baseline in mean SDS total score (14.4 point reduction at week 12) 81.8% response (reduction of ≥ 15 points in CAPS-5 score), 63.6% remission (total CAPS-5 ≤ 20) rates at week 4... Read More

LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Mindful Health Solutions (MHS), one of the US’s leading providers of innovative behavioral health care, today announced that they have entered into a research collaboration agreement to inform the development of a scalable... Read More

LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Journey Clinical, a leading psychedelic-assisted psychotherapy platform with the largest network of licensed therapists focused on psychedelics in the US, today announced they have entered into a research collaboration... Read More

LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that Board Chair and co-founder George Goldsmith and fellow co-founder Ekaterina Malievskaia have resigned their seats on the company’s board of directors, effective March 29, 2024. David Norton, lead... Read More

Highlights: COMP360 phase 3 pivotal program ongoing; COMP005 trial top-line data now expected in fourth quarter 2024, COMP006 remains on track for top-line data in mid-2025 Teri Loxam to assume Chief Financial Officer role on March 1, 2024 Cash position of $220.2 million at December 31, 2023, additional $31.4 million net cash raised to date in first quarter 2024 Conference call February 29 at 8:00 am ET (1:00 pm UK) LONDON,... Read More

LONDON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Hackensack Meridian Health (“HMH”), a leading not-for-profit health care organization and the largest, most comprehensive and truly integrated network in New Jersey, today announced that that they have entered into a... Read More

LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Greenbrook TMS Inc. (NASDAQ: GBNH) (“Greenbrook TMS”), a leading provider of Transcranial Magnetic Stimulation and Spravato ® (esketamine nasal spray)—FDA-cleared, non-invasive therapies for the treatment of major... Read More

LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that an initial data readout showed that investigational COMP360 psilocybin treatment was well-tolerated in a phase 2 clinical trial of people living with post-traumatic stress disorder (PTSD). This is... Read More

LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will be based in the company’s New York City office. Teri will serve as an advisor during the... Read More

LONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a paper in JAMA Psychiatry that demonstrates the potential for investigational COMP360 psilocybin treatment in treatment-resistant bipolar type II disorder (bipolar II). Results from the... Read More

UK sites to participate in part of pivotal phase 3 program following Medicines and Healthcare Regulatory Agency approval of study Research will take place in the UK, including at the newly opened Centre for Mental Health Research and Innovation in London, developed in partnership with South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, Psychology & Neuroscience at King’s College London LONDON,... Read More

Highlights: COMP360 Phase 3 pivotal program ongoing with expanding European clinical sites Secured up to $285 million private placement financing with $125 million upfront Cash position at September 30, 2023 of $248.0 million Conference call on November 2 at 8:00 am ET (12:00 pm UK) LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating... Read More

LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS” or the “company”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that Mike Falvey, Chief Financial Officer, will depart the company on November 3, 2023, to pursue other opportunities. Mary-Rose Hughes, current Vice President of Finance at COMPASS, will... Read More

LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September 18, 2023. Ms. Karydas is President and Chief Financial Officer at Flare Therapeutics Inc., a privately held biotechnology... Read More

LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a new paper in Pyschopharmacology, which showed the results of a retrospective study that evaluates the potential of its AI technologies to support investigational COMP360 psilocybin... Read More

Transaction led by healthcare specialist investors, TCGX and Aisling Capital $125 million financing upfront with up to an additional $160 million tied to exercise of warrants Net proceeds from financing expected to extend cash runway into late 2025 LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in... Read More

Hghlights: COMP360 Phase 3 pivotal program ongoing and on track CPT ® III code for in-person psychedelic therapy support accepted by the American Medical Association Cash position at June 30, 2023 of $148.2 million Term loan facility up to $50 million secured Conference call today at 8:00 am ET (1:00 pm UK) LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company... Read More

LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a paper in Nature Medicine that demonstrates the potential for COMP360 psilocybin treatment in anorexia nervosa. The investigator-initiated open-label study was conducted by Drs. Walter Kaye... Read More

Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 LONDON, July 17, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that positive... Read More

Leading psychiatrists and researchers examine common assumptions about the term “psychedelic-assisted psychotherapy” and the role of psychotherapy when evaluating psilocybin treatment. Authors highlight the need for clarity in terminology and definition to accurately assess the efficacy and safety of psilocybin treatment. LONDON, July 13, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a... Read More

New code will facilitate reimbursement for psychedelic therapy in the US, if approved COMPASS Pathways to hold webinar on new code on Tuesday, July 11, 8:00 am EDT (1:00 pm BST) LONDON, July 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that the American Medical... Read More

PTAB rejects two requests for rehearing of the USPTO's decision denying institution of post-grant review (PGR) of U.S. patent numbers 10,947,257 (‘257 Patent) and 10,954,259 (‘259 Patent). In June 2022, the PTAB denied institution of the PGRs finding the challenger failed to establish that any of the claims of ‘257 Patent and ‘259 Patent are unpatentable. LONDON, June 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc... Read More

LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation, today announced that Co-founder and Chief Innovation Officer Dr. Ekaterina Malievskaia will step down from her executive role effective June 16, 2023. She will remain a member of the COMPASS Pathways Board of Directors, while her... Read More

More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological support Open label phase 2 study, conducted by Sunstone Therapies and scheduled to be presented at the ASCO annual meeting on June 5, is believed to be the longest clinical study of psilocybin ever conducted LONDON, May 26, 2023 (GLOBE NEWSWIRE) -- COMPASS... Read More

Highlights: COMP360 Phase 3 pivotal program underway, patients have been treated in both trials CPT® III code for in-person psychedelic therapy support accepted by the American Medical Association Cash position at 31 March 2023 of $117.1 million, additional $26.9 million net cash raised through ATM facility to date in the second quarter Conference call today at 8:00am ET (1:00pm UK) LONDON, May 11, 2023 (GLOBE NEWSWIRE) --... Read More

LONDON and SAN JOSE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, and MAPS Public Benefit Corporation (MAPS PBC), a clinical-stage company dedicated to changing the way mental health conditions are treated, today announced that the American Medical Association (AMA)... Read More

LONDON, April 10, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the 22 nd Annual Needham Virtual Healthcare Conference at 9:30 am ET on April 19, 2023. A live audio webcast of the presentation will be accessible from the “Events” page of the... Read More

LONDON, March 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three upcoming events as follows: Cowen 43 rd Annual Health Care Conference: ‘Neuropsych Panel’ at 12:50pm ET on March 6, 2023 and host investor meetings Oppenheimer 33 rd Annual... Read More

Highlights: Phase 3 pivotal program underway - important updates announced Phase 3 long term follow up defined Cash position at 31 December 2022 of $143.2 million Conference call today at 8:00am ET (1:00pm UK) LONDON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today... Read More

LONDON, Feb. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and year-end 2022, and provide an update on recent business developments on 28 February 2023. The management team will host a conference call at 8:00am ET... Read More

12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II bipolar disorder New data from COMPASS’ phase 2b trial, also presented at ACNP, validate potential of COMP360 psilocybin therapy in treatment-resistant depression LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2022, and provide an update on recent business developments on 3 November 2022. The management team will host a conference call at 8:00am ET (1:00pm UK) on 3 November. To access the call, please... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the Phase 3 pivotal program design for COMP360 psilocybin therapy in treatment resistant depression (TRD) during a virtual Capital Markets Day. The session, attended by members of COMPASS Pathways’ executive leadership and key opinion leaders, included a... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today the agenda for its virtual Capital Markets Day on 12 October 2022 at 8:00 am ET (1 pm UK). Topics to be covered at the event span the design of the Phase 3 program for COMP360 psilocybin therapy in treatment-resistant depression (TRD), TRD treatment... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at Jefferies Innovation in Mental Health Summit at 8:30am ET on 22 September 2022. A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the COMPASS website.... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three upcoming investor events as follows: Citi 17 th Annual BioPharma Conference: panel at 10:30 am ET on 7 September 2022 and host investor meetings Morgan Stanley 20 th Annual Global Healthcare Conference: fireside chat... Read More

Highlights: Kabir Nath appointed as Chief Executive Officer Phase III program submitted to FDA and under review COMP360 phase II study in anorexia nervosa launched Cash position at 30 June 2022 of $207.2 million Conference call today at 8:00am ET (1:00pm UK) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that COMPASS granted a non-qualified share option to purchase an aggregate of 600,000 ordinary shares, nominal value £0.008 each, in the capital of the Company to Kabir Nath, COMPASS’s newly appointed chief executive officer. In accordance with... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows: BTIG Biotechnology Conference: host investor meetings on 9 August 2022 Canaccord Annual Growth Conference: presentation at 8:30 am ET on 10 August 2022 and host investor meetings A live... Read More

Multi-centre, d ouble-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therap y in anorexia nervosa for which there is currently no approved pharmacological treatment option COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it has launched a... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2022, and provide an update on recent business developments on 4 August 2022. The management team will host a conference call at 8:00am ET (1:00pm UK) on 4 August. To access the call, please... Read More

Kabir Nath will build upon COMPASS’ success and lead the development of novel models of care to accelerate patient access to evidence-based innovation in mental health care George Goldsmith remains COMPASS’ Chairman COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Kabir... Read More

Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today presented positive data from the largest randomised, controlled, double-blind study of psilocybin therapy ever completed, at the American... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows: Citi’s Biopharma Virtual Co-Panel Day: panel “Mood Disorders/Mental Health Panel” at 11:00 am ET on 18 May 2022 HC Wainwright Global Investments Conference: presentation at 9:00 am ET on 24... Read More

Highlights: End of phase II meeting held with FDA Award of Innovation Passport as part of the UK MHRA Innovative Licensing and Access Pathway ILAP Finalising phase III in TRD program design to be ready for second half of 2022 Pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust, to create The Centre for Mental Health Research and Innovation in the UK Cash position at 31 March... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be funding an investigator-initiated study that will use COMP360 psilocybin to explore how psilocybin affects specific brain pathways in autistic adults. This will be the first ever mechanistic study of psilocybin in autistic adults. The... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2022, and provide an update on recent business developments on 10 May 2022. The management team will host a conference call at 8:00am ET (1:00pm UK) on 10 May. The call can be accessed by dialing... Read More

Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that positive data demonstrating the potential of COMP360 psilocybin therapy in anorexia nervosa and... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it is partnering with One Mind, a leading mental health research non-profit based in California, to sponsor three “2022 One Mind - COMPASS Rising Stars Awards”. The One Mind Rising Star Awards are given each year to promising early career... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will present at the 21 st Annual Needham Virtual Healthcare Conference at 2:15pm ET on 14 April 2022. A webcast of the presentation will be available on the “Events” page of the Investors section of the COMPASS website. A... Read More

Pioneering c ollaboration with King’s College London and South London and Maudsley NHS Foundation Trust COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has formed a long-term strategic partnership to launch The Centre for Mental Health Research and Innovation (“the Centre”) to accelerate psychedelic research... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in and attend one-on-one meetings at two investor conferences as follows: Cowen 42 nd Annual Health Care Conference: “Neuropsych” panel at 9:10am ET on 7 March 2022 Roth 34 th Annual Conference: fireside... Read More

Highlights: Positive results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD); rapid and sustained response for patients receiving a single 25mg dose of COMP360 psilocybin with psychological support Positive results from open-label study of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in TRD Launch of phase II study of COMP360 psilocybin therapy for post-traumatic... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and full year 2021, and provide an update on recent business developments on 24 February 2022. The management team will host a conference call at 8:00am ET (1:00pm UK) on 24 February. The call can... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, and Sermo, a global leader in physician insights, today announced findings from a survey of Sermo physician members that showed two thirds (66%) of doctors surveyed believe psilocybin therapy has potential therapeutic benefit for patients with treatment-resistant depression... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference, available on demand from 10 to 13 January. An audio webcast of the fireside chat will be available on the “Events” page of the Investors section of the... Read More

Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, shared results today of a phase I study showing the feasibility of administering COMP360 psilocybin to... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market ® (Nasdaq ® )... Read More

M atthew Owen s appointed General Counsel and Chief Legal Officer ; Lars Wilde, Chief Business Officer and Co-founder, to move into senior advis ory role COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has appointed Matthew Owens as General Counsel and Chief Legal Officer. Mr Owens... Read More

Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trial All patients tolerated COMP360 psilocybin therapy well COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the results from its... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed Michael Falvey as Chief Financial Officer, replacing Piers Morgan when he leaves the company, as previously announced, at the end of the year. Michael Falvey is highly experienced in delivering financial and operational excellence... Read More

Positive topline results validated by additional analyses Patient improvements beyond reduction of depression symptoms Further insights into timing and circumstance of adverse events demonstrate COMP360 psilocybin therapy was generally well-tolerated COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three investor conferences as follows: Evercore ISI 4 th Annual HEALTHCONx Virtual Conference: fireside chat at 9:40am ET on 1 December 2021. The fireside chat will feature Augustus John Rush MD, Adjunct Professor in the... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office (USPTO). This is COMPASS’s 10 th patent overall, with five now granted in the US, two in the UK, one in Germany and two in Hong Kong. The new patent, US Patent No... Read More

Highlights: Positive topline results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression; rapid and sustained response for patients receiving a single 25mg dose of COMP360 psilocybin with psychological support Launch of phase II study of COMP360 psilocybin therapy for PTSD Positive signals from Maryland Oncology Hematology open-label investigator initiated study of COMP360 psilocybin therapy... Read More

Largest randomised, controlled, double-blind psilocybin therapy study ever completed shows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological support COMPASS management team to host an investor conference call today at 1.00pm UK (8.00am ET COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2021, and provide an update on recent business developments, on 9 November 2021. The management team will host a conference call at 1:00pm UK (8.00am ET) on 9 November. The call can be accessed by... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be conducting a phase II clinical trial to assess the safety and tolerability of COMP360 psilocybin therapy in post-traumatic stress disorder (PTSD). The study expands COMPASS’s research pipeline in psilocybin therapy with COMP360, the... Read More

Investigator-initiated study shows remission in major depression symptoms for 50% of participants COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed the topline data shared today from an open-label study of psilocybin therapy for depression in cancer patients. Within one week of a single administration... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fourth patent by the US Patent and Trademark Office (USPTO). This is COMPASS’s first patent with claims covering its Form A hydrate psilocybin. The Form A hydrate is distinct from the anhydrate psilocybin for which... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming investor conferences as follows: Maxim Group and M-Vest Mental Health Advances in Mental Health, Psychedelics and Non-Psychedelics Virtual Conference: “Clinics and Commercialization: Scaling psychedelics to... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has acquired an intellectual property (IP) portfolio including patent applications covering a variety of psychedelic and empathogenic substances. The IP was developed together with inventor Matthias Grill PhD, founder and CEO of MiHKAL GmbH in... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris, the research scientist and film-maker, as a full-time consultant, who will be working primarily at the COMPASS Discovery Center, based at University of the Sciences in Philadelphia (USciences) in the United States. Mr Morris will be... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three investor conferences in September as follows: Citi 16th Annual BioPharma Virtual Conference: “Psychedelic Medicines for Mental Health Conditions” panel on 8th September at 2:20pm ET Morgan Stanley 19th Annual Global... Read More

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021 Partnership being developed with leading UK institutions to accelerate psychedelic research and develop new models of mental health care in the UK Guy Goodwin appointed Chief Medical Officer and Danielle Schlosser appointed Senior Vice-President, Clinical Innovation... Read More

London, UK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2021, and provide an update on recent business developments, on 11 August 2021. The management team will host a conference call at 1:00pm UK (8.00am... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in fireside chats at two investor conferences in August as follows: BTIG Virtual Biotechnology Conference: 10:30am ET on 9 August Canaccord Genuity 41 st Annual Growth Conference: 2:00pm ET on 10 August... Read More

COMPASS announces changes to its Executive Team COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed eminent psychiatrist, Professor Guy Goodwin FMedSci, as Chief Medical Officer. Guy Goodwin is Emeritus Professor of Psychiatry at The University of Oxford. He was formerly WA Handley... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed Danielle Schlosser PhD as Senior Vice-President, Clinical Innovation. Dr Schlosser will lead COMPASS’s Therapy Research and Training team, bringing her clinical experience in behavioural health and experience in digital health... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Lars Wilde, President, Chief Business Officer, and Co‑founder, will participate in a fireside chat at 10:10am ET at Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on 13 July. Members of the COMPASS management team will be... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has signed a Memorandum of Understanding (MoU) with South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King’s College London, aimed at advancing psychedelic research and developing... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, launched a new podcast today – “Everyone has a story: talking about mental health”. The podcast will feature influential guests who will talk about their mental health journeys, share their personal stories, and discuss critical issues in mental health care,... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has completed psilocybin administration to the target 216 patients in its phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression. This is the world’s largest psilocybin therapy trial to date. The trial... Read More

Programme aims to support students from under-represented ethnic groups COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has become a Founding Supporter of the British Neuroscience Association’s (BNA) inaugural Scholars programme, which aims to support students from under-represented ethnic groups to thrive in... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in two investor conferences in June. George Goldsmith, Chairman, CEO and Co-founder, and Lars Wilde, President, Chief Business Officer, and Co-founder, will be participating in a fireside chat at the JMP... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult volunteers with support from specially trained therapists. The data ( see... Read More

Highlights: New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder Two further US patents granted Equity financing raises gross proceeds of $144 million Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD) on track to report data by end of 2021 Wayne J Riley MD... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2021, and provide an update on recent business developments, on 13 May 2021. The management team will host a conference call at 1:00pm UK(8.00am ET) on 13 May. The call can be accessed by dialing... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of its public offering of 4,000,000 American Depositary Shares (“ADSs”) representing 4,000,000 ordinary shares at a public offering price of $36.00 per ADS for total gross proceeds of $144.0 million. All ADSs sold in the offering were... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the launch of a proposed public offering of 4,000,000 American Depositary Shares (“ADSs”), each representing one ordinary share. Each of the ADSs is being offered by COMPASS. COMPASS expects to grant the underwriters a 30-day option to purchase... Read More

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine (NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD). The study was... Read More

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that George Goldsmith, Chairman, CEO and Co‑founder, and Lars Wilde, President, Chief Business Officer, and Co‑founder, will present a corporate update at 8:00am ET on 15 April at the 20 th Annual Needham Virtual Healthcare Conference. Members of the COMPASS... Read More

COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has appointed Wayne J Riley MD to its Board of Directors. Dr Riley is President of the State University of New York (SUNY) Downstate Health Sciences University,... Read More

COMPASS Pathways granted two US patents COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted two new patents by the US Patent and Trademark Office (USPTO). These patents cover oral formulations of COMPASS’s synthetic psilocybin in the treatment of major depressive disorder... Read More

Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD) on track to report data by end of 2021 First Centre of Excellence, a research facility and innovation lab, established at Sheppard Pratt (Baltimore, Maryland, US) Discovery Center expanded into network of world-leading scientists developing new optimised psychedelic compounds Conference call today at 1.00pm GMT (8.00am ET) COMPASS... Read More

COMPASS Pathways plc (Nasdaq: CMPS) , a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and year ended 31 December 2020, and provide an update on recent business developments, on 9 March 2021. The management team will host a conference call at 1:00pm GMT (8.00am ET) on 9 March. The... Read More

George Goldsmith, Chairman & CEO, to participate in Neuropsych Panel discussion COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in Cowen's 41st Annual Health Care Conference. George Goldsmith, Chairman, CEO and Co‑founder, will participate in the... Read More